phrykt

Corbus Pharmaceuticals Holdings, Inc. (CRBP): who owns it and who trades it

As of Nov 16, 2026, CRBP insiders reported 14 open-market sales worth $2.7M and 3 purchases worth $126K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Cormorant Asset Management, LP (Other), with $1.7M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Corbus Pharmaceuticals Holdings

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CRBP

108 funds and institutions reported CRBP shares worth $130M at the end of Q2 2026, about 78% of the company. The largest holder is Cormorant Asset Management, LP with 13.2%.

Funds and institutions (13F) 78%Everyone else 22%

10 largest owners, by share of the company

Cormorant Asset Management, LP13.2%
Orbimed Advisors LLC9.8%
BlackRock, Inc.7.5%
Aberdeen Group plc7.5%
Vanguard Capital Management LLC4.3%
Jones Hill Capital LP3.7%
Prosight Management, LP3.7%
Stonepine Capital Management, LLC2.4%
Geode Capital Management, LLC2.4%
ADAR1 Capital Management, LLC2.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Cormorant Asset Management, LP2.34M13.22%$22MNo change
Orbimed Advisors LLC1.74M9.80%$16.3MNo change
BlackRock, Inc.1.33M7.51%$12.5M+390%
Aberdeen Group plc1.32M7.45%$12.4MNo change
Vanguard Capital Management LLC760,9404.29%$7.1M+4%
Jones Hill Capital LP653,5723.68%$6.1M–
Prosight Management, LP650,0003.66%$6.1M-7%
Stonepine Capital Management, LLC425,0002.40%$4M+11%
Geode Capital Management, LLC423,3742.39%$4M+126%
ADAR1 Capital Management, LLC421,7872.38%$4M+27%
Diadema Partners LP301,2641.70%$2.8M-32%
Susquehanna International Group, LLP293,2031.65%$2.8M-12%
State Street Corp254,6721.44%$2.4M+270%
Dimensional Fund Advisors LP190,2141.07%$1.8M+39%
Exome Asset Management LLC184,9141.04%$1.7M-21%
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.151,6400.85%$1.4M-5%
Jane Street Group, LLC139,1330.78%$1.3M+90%
Northern Trust Corp124,9060.70%$1.2M+201%
Vanguard Fiduciary Trust Co112,3970.63%$1.1M+17%
Vanguard Portfolio Management LLC111,3020.63%$1M+357%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, CRBP insiders reported $126K of open-market purchases and $2.7M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$126K
3 trades, 1 people
Sales, 12 months
$2.7M
14 trades, 10 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Oct 29, 2026
Filed Nov 2, 2026

Purchases and sales by month

$1.7M$1.7MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 29, 2026Cormorant Asset Management, LP +2OtherSale425,000$4.10$1.7MForm 4
Sep 14, 2026Yong BenDirectorSale2,000$7.84$15.7KForm 4
Aug 11, 2026Nishant C SaxenaChief Business OfficerPurchase2,600$9.63$25KForm 4
Aug 7, 2026Yuval CohenCEOSale17,000$10.08$171KForm 4
Aug 7, 2026Sean F. MoranCFOSale12,000$10.08$121KForm 4
Jun 10, 2026Winston KungDirectorSale2,026$7.91$16KForm 4
Jun 10, 2026John Kenneth JenkinsDirectorSale4,800$7.91$38KForm 4
Jun 10, 2026Anne AltmeyerDirectorSale2,412$7.91$19.1KForm 4
Jun 3, 2026Nishant C SaxenaChief Business OfficerPurchase9,000$7.58$68.2KForm 4
Jun 2, 2026Nishant C SaxenaChief Business OfficerPurchase4,500$7.33$33KForm 4
Mar 2, 2026Dominic SmethurstChief Medical OfficerSale6,097$8.30$50.6KForm 4
Feb 17, 2026Ian HodgsonChief Operating OfficerSale847$7.38$6.3KForm 4
Feb 13, 2026Sean F. MoranCFOSale4,701$7.78$36.6KForm 4
Feb 13, 2026Yuval CohenCEOSale13,871$7.78$108KForm 4
Feb 3, 2026Dominic SmethurstChief Medical OfficerSale3,285$8.09$26.6KForm 4
Feb 3, 2026Ian HodgsonChief Operating OfficerSale2,415$8.09$19.5KForm 4
Dec 11, 2025Bihua Chen +210% ownerSale30,029$11.46$344KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Cormorant Asset Management, LPOther–$1.7MOct 29, 2026
Bihua Chen10% owner–$344KDec 11, 2025
Yuval CohenChief Executive Officer, Director–$279KAug 7, 2026
Sean F. MoranChief Financial Officer–$158KAug 7, 2026
Nishant C SaxenaChief Business Officer$126K–Aug 11, 2026
Dominic SmethurstChief Medical Officer–$77.2KMar 2, 2026
John Kenneth JenkinsDirector–$38KJun 10, 2026
Ian HodgsonChief Operating Officer–$25.8KFeb 17, 2026
Anne AltmeyerDirector–$19.1KJun 10, 2026
Winston KungDirector–$16KJun 10, 2026
Yong BenDirector–$15.7KSep 14, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CRBP short interest

High short interest. 16.8% of CRBP shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 171%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.24M CRBP shares were sold short, 16.8% of the shares outstanding, up 19.5% from the report before. At the average daily volume of 933,143 shares, buying them all back would take about 3.5 trading days (days to cover).

Shares short, % of all shares

16.8%May 15Oct 3018.3%

Days to cover

3.5May 15Oct 3010.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.24M16.77%+20%933,1433.5
Oct 15, 20262.71M14.03%-11%958,7652.8
Sep 30, 20263.05M15.80%+11%791,3863.9
Sep 15, 20262.76M14.27%+23%1.79M1.5
Aug 31, 20262.25M11.61%+5%611,6173.7
Aug 14, 20262.15M11.10%-7%355,4546.0
Jul 31, 20262.30M12.96%+10%245,1789.4
Jul 15, 20262.10M11.82%+8%355,4845.9
Jun 30, 20261.95M10.97%+23%571,4963.4
Jun 15, 20261.58M8.91%+3%465,2813.4
May 29, 20261.53M8.62%+28%1.07M1.4
May 15, 20261.20M6.74%-15%306,6973.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Corbus Pharmaceuticals Holdings company events

Corbus Pharmaceuticals Holdings filed 17 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Oct 15, 2026AnnouncementShared information with investors. Filing
  3. Sep 14, 2026AnnouncementThe Company announced positive topline data from the CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. Filing
  4. Aug 6, 2026ResultsReleased financial results. Filing
  5. Jul 6, 2026AgreementCorbus Pharmaceuticals Holdings, Inc. entered into an employment agreement with Leonardo Viana Nicacio, MD, effective August 3, 2026, and will be effective for a period of two (2) years from the date thereof. Filing
  6. May 26, 2026AnnouncementThe Company announced updated data from its Phase 1/2 clinical study of CRB-701 (SYS6002), a next-generation Nectin-4 targeted ADC. The new data demonstrate robust activity in the second line (2L) setting of two solid tumor types that express high levels of Nectin-4 and are primarily driven by… Filing
  7. May 21, 2026LeadershipThe Compensation Committee granted Brent Pfeiffenberger the following initial equity awards under the Corbus Pharmaceuticals Holdings, Inc. 2024 Equity Incentive Plan in connection with his appointment to the Board: (i) a nonqualified stock option to purchase 24,700 shares of the Company’s common… Filing
  8. May 14, 2026LeadershipThe board of directors of Corbus Pharmaceuticals Holdings, Inc., upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Brent Pfeiffenberger, age 48, to serve as a member of the Board, thereby expanding the Board to seven members. Filing
  9. May 12, 2026ResultsReleased financial results. Filing
  10. Apr 16, 2026LeadershipCorbus Pharmaceuticals Holdings, Inc. entered into amended and restated employment agreements, effective April 15, 2026, with certain of the Company’s executive officers: Yuval Cohen, Ph.D., Chief Executive Officer and Sean Moran, Chief Financial Officer. Filing
  11. Apr 14, 2026AnnouncementThe Company announced Last Patient First Visit in the Company’s CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. Filing
  12. Apr 7, 2026LeadershipCorbus Pharmaceuticals Holdings, Inc. was notified by Dominic Smethurst, the Company’s Chief Medical Officer, of his resignation, effective June 30, 2026. Filing
  13. Mar 9, 2026ResultsReleased financial results. Filing
  14. Feb 25, 2026AnnouncementShared information with investors. Filing
  15. Jan 12, 2026AnnouncementShared information with investors. Filing
  16. Dec 18, 2025LeadershipAlan Holmer provided Corbus Pharmaceuticals Holdings, Inc. with notice of his resignation from the Board of Directors, effective December 31, 2025, due to retirement. Filing
  17. Dec 11, 2025AnnouncementThe Company announced the completion of the single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a study of CRB-913 and the initiation of a Phase 1b dose-range finding study, with completion expected in summer 2026. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Corbus Pharmaceuticals Holdings financials

Famous investors that hold CRBP

3 of the 50 well-known investors we track reported holding CRBP in their latest 13F filing. The largest position is Jim Simons's, worth $647K.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 202694,900$647K0.0%-14%
Steve Cohen · Point72 Asset ManagementQ3 202689,312$609K0.0%New
Israel Englander · Millennium ManagementQ3 202681,269$554K0.0%+611%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named CRBP in the last 120 days.

FiledHolderFormStake
Nov 13, 2026MPM BioImpact LLC13G8.6%
Nov 13, 2026MPM BioImpact LLC13G8.6%
Nov 2, 2026Cormorant Asset Management, LP13G/A7.8%
Nov 2, 2026Cormorant Asset Management, LP13G/A7.8%
Oct 29, 2026Aberdeen Group plc13G/A0.0%
Oct 29, 2026Aberdeen Group plc13G/A0.0%

Questions about Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock

Who owns the most CRBP stock?

The largest reported owner of Corbus Pharmaceuticals Holdings, Inc. (CRBP) is Cormorant Asset Management, LP, with 13.2% of the company. In total, 108 funds and institutions reported holding CRBP at the end of Q2 2026, together about 78% of the shares. See the largest owners.

Are CRBP insiders buying or selling?

In the last 12 months, CRBP insiders reported 3 open-market purchases worth $126K and 14 sales worth $2.7M. The latest trade was on Oct 29, 2026. See every trade.

What is the short interest in CRBP?

As of Oct 30, 2026, 3.24M CRBP shares were sold short, 16.8% of the shares outstanding, up 19.5% from the report before. At the average daily volume of 933,143 shares, buying them all back would take about 3.5 trading days (days to cover). See the history.

Which famous investors hold CRBP?

3 of the 50 well-known investors we track reported CRBP in their latest 13F filing, including Jim Simons, Steve Cohen, Israel Englander. The largest position is worth $647K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.